Genetica della neurofibromatosi tipo 1 (NF1)

Translated title of the contribution: Genetics of neurofibromatosis type 1 (NF1)

Livia Garavelli, Lucia Grassi, Ada Donadio, Mauro Sigorini, Giacomo Banchini

Research output: Contribution to journalArticle

Abstract

Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder characterised by cafè au lait spots, multiple neurofibromas and Lisch nodules of the iris, with marked variability of expression. The NF1 gene is located at 17q11.2, spans 350 kb genomic DNA and comprises 60 exons encoding a 11-13 kb transcript (Viskochil et al.). Four alternatively spliced NF1 transcripts have been identified and they show differential expression in various tissues. NF1 gene is a member of the tumor suppressor gene family. The protein encoded by NF1, neurofibromin, has a domain homologous to the GTPase activating protein (GAP) family, and downregulates ras activity. Neurofibromin is involved in the control of cellular growth and differentiation and germline mutation analysis has shown that around 82% of all the fully characterised NF1 specific mutations so far predict severe truncation of neurofibromin. The current demand for molecular diagnosis of NF1 is low. Many couples would probably request a prenatal diagnosis if it could predict disease severity. Molecular prediction of disease severity and prognosis may either be very complicated or even impossible. Presymptomatic DNA diagnosis is probably not going to be in huge demand because the clinical diagnosis of NF1 is usually straightforward, even in early childhood. Further knowledge of the gene function may also lead to the development of new therapy for the disease.

Original languageItalian
Pages (from-to)89-95
Number of pages7
JournalActa Biomedica
Volume71
Issue number3-4
Publication statusPublished - 2000

Fingerprint

Neurofibromatosis 1
Neurofibromin 1
Neurofibromatosis 1 Genes
GTPase-Activating Proteins
Neurofibromatoses
Germ-Line Mutation
DNA
Iris
Tumor Suppressor Genes
Prenatal Diagnosis
Exons
Down-Regulation
Mutation
Growth
Genes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Garavelli, L., Grassi, L., Donadio, A., Sigorini, M., & Banchini, G. (2000). Genetica della neurofibromatosi tipo 1 (NF1). Acta Biomedica, 71(3-4), 89-95.

Genetica della neurofibromatosi tipo 1 (NF1). / Garavelli, Livia; Grassi, Lucia; Donadio, Ada; Sigorini, Mauro; Banchini, Giacomo.

In: Acta Biomedica, Vol. 71, No. 3-4, 2000, p. 89-95.

Research output: Contribution to journalArticle

Garavelli, L, Grassi, L, Donadio, A, Sigorini, M & Banchini, G 2000, 'Genetica della neurofibromatosi tipo 1 (NF1)', Acta Biomedica, vol. 71, no. 3-4, pp. 89-95.
Garavelli L, Grassi L, Donadio A, Sigorini M, Banchini G. Genetica della neurofibromatosi tipo 1 (NF1). Acta Biomedica. 2000;71(3-4):89-95.
Garavelli, Livia ; Grassi, Lucia ; Donadio, Ada ; Sigorini, Mauro ; Banchini, Giacomo. / Genetica della neurofibromatosi tipo 1 (NF1). In: Acta Biomedica. 2000 ; Vol. 71, No. 3-4. pp. 89-95.
@article{71d0c393c3804f7f9a863391b48ba24d,
title = "Genetica della neurofibromatosi tipo 1 (NF1)",
abstract = "Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder characterised by caf{\`e} au lait spots, multiple neurofibromas and Lisch nodules of the iris, with marked variability of expression. The NF1 gene is located at 17q11.2, spans 350 kb genomic DNA and comprises 60 exons encoding a 11-13 kb transcript (Viskochil et al.). Four alternatively spliced NF1 transcripts have been identified and they show differential expression in various tissues. NF1 gene is a member of the tumor suppressor gene family. The protein encoded by NF1, neurofibromin, has a domain homologous to the GTPase activating protein (GAP) family, and downregulates ras activity. Neurofibromin is involved in the control of cellular growth and differentiation and germline mutation analysis has shown that around 82{\%} of all the fully characterised NF1 specific mutations so far predict severe truncation of neurofibromin. The current demand for molecular diagnosis of NF1 is low. Many couples would probably request a prenatal diagnosis if it could predict disease severity. Molecular prediction of disease severity and prognosis may either be very complicated or even impossible. Presymptomatic DNA diagnosis is probably not going to be in huge demand because the clinical diagnosis of NF1 is usually straightforward, even in early childhood. Further knowledge of the gene function may also lead to the development of new therapy for the disease.",
author = "Livia Garavelli and Lucia Grassi and Ada Donadio and Mauro Sigorini and Giacomo Banchini",
year = "2000",
language = "Italian",
volume = "71",
pages = "89--95",
journal = "Acta Biomedica de l'Ateneo Parmense",
issn = "0392-4203",
publisher = "L'Ateneo Parmense",
number = "3-4",

}

TY - JOUR

T1 - Genetica della neurofibromatosi tipo 1 (NF1)

AU - Garavelli, Livia

AU - Grassi, Lucia

AU - Donadio, Ada

AU - Sigorini, Mauro

AU - Banchini, Giacomo

PY - 2000

Y1 - 2000

N2 - Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder characterised by cafè au lait spots, multiple neurofibromas and Lisch nodules of the iris, with marked variability of expression. The NF1 gene is located at 17q11.2, spans 350 kb genomic DNA and comprises 60 exons encoding a 11-13 kb transcript (Viskochil et al.). Four alternatively spliced NF1 transcripts have been identified and they show differential expression in various tissues. NF1 gene is a member of the tumor suppressor gene family. The protein encoded by NF1, neurofibromin, has a domain homologous to the GTPase activating protein (GAP) family, and downregulates ras activity. Neurofibromin is involved in the control of cellular growth and differentiation and germline mutation analysis has shown that around 82% of all the fully characterised NF1 specific mutations so far predict severe truncation of neurofibromin. The current demand for molecular diagnosis of NF1 is low. Many couples would probably request a prenatal diagnosis if it could predict disease severity. Molecular prediction of disease severity and prognosis may either be very complicated or even impossible. Presymptomatic DNA diagnosis is probably not going to be in huge demand because the clinical diagnosis of NF1 is usually straightforward, even in early childhood. Further knowledge of the gene function may also lead to the development of new therapy for the disease.

AB - Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder characterised by cafè au lait spots, multiple neurofibromas and Lisch nodules of the iris, with marked variability of expression. The NF1 gene is located at 17q11.2, spans 350 kb genomic DNA and comprises 60 exons encoding a 11-13 kb transcript (Viskochil et al.). Four alternatively spliced NF1 transcripts have been identified and they show differential expression in various tissues. NF1 gene is a member of the tumor suppressor gene family. The protein encoded by NF1, neurofibromin, has a domain homologous to the GTPase activating protein (GAP) family, and downregulates ras activity. Neurofibromin is involved in the control of cellular growth and differentiation and germline mutation analysis has shown that around 82% of all the fully characterised NF1 specific mutations so far predict severe truncation of neurofibromin. The current demand for molecular diagnosis of NF1 is low. Many couples would probably request a prenatal diagnosis if it could predict disease severity. Molecular prediction of disease severity and prognosis may either be very complicated or even impossible. Presymptomatic DNA diagnosis is probably not going to be in huge demand because the clinical diagnosis of NF1 is usually straightforward, even in early childhood. Further knowledge of the gene function may also lead to the development of new therapy for the disease.

UR - http://www.scopus.com/inward/record.url?scp=0034570766&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034570766&partnerID=8YFLogxK

M3 - Articolo

C2 - 11424621

AN - SCOPUS:0034570766

VL - 71

SP - 89

EP - 95

JO - Acta Biomedica de l'Ateneo Parmense

JF - Acta Biomedica de l'Ateneo Parmense

SN - 0392-4203

IS - 3-4

ER -